Teladoc Health Inc. v. Data Health Partners Inc.

Teladoc Health Inc. v. Data Health Partners Inc. is an Inter Partes Review (IPR) proceeding (IPR2024-00616) before the Patent Trial and Appeal Board (PTAB) challenging the validity of US Patent 11144554. Teladoc Health Inc., a prominent publicly traded virtual healthcare company offering a range of telehealth and telemedicine services, initiated this IPR as the petitioner. Its services encompass general medical care, mental health support, and chronic condition management, including diabetes. Data Health Partners Inc., the patent owner and defendant in this IPR, describes itself as a digital therapeutics company. Founded in early 2022, Data Health Partners acquired a technology called "REBOOT," an evidence-based behavioral modification and goal mastery system protected by several patents. While they claim to be an operating company, their recent formation and swift assertion of acquired patents suggest a business model focused heavily on patent enforcement and licensing.

This IPR is directly linked to an underlying patent infringement lawsuit, Data Health Partners, Inc. v. Teladoc Health, Inc., Case No. 1:23-cv-00160, filed in the U.S. District Court for the District of Delaware. In that litigation, Data Health Partners accuses Teladoc of infringing US Patent 11144554, along with related patents (11151142, 11675791, and 11809431), through its Livongo Blood Glucose Meter and diabetes management platform. US Patent 11144554, titled "Platform for Optimizing Goal Progression," broadly covers a networked system for tracking an individual's progress towards specific goals, particularly within behavioral health contexts, by collecting data, performing automated analysis, and providing user feedback.

The procedural posture of this case is an IPR before the PTAB, which acts as an administrative body within the USPTO to review the patentability of claims in an issued patent. The current status of IPR2024-00616 is a Final Written Decision. The use of an IPR by Teladoc is a common defensive strategy to challenge the validity of asserted patents in parallel to ongoing district court litigation. This case is notable given Teladoc's prominent position in the rapidly evolving digital health and virtual care industry, and it highlights the increasing intellectual property disputes surrounding chronic condition management technologies. The linkage between the PTAB IPR and the District of Delaware litigation underscores the dual-track approach often employed in modern patent disputes, where validity challenges are pursued concurrently with infringement claims.

Key Legal Developments and Outcome for Teladoc Health Inc. v. Data Health Partners Inc.

This case involves parallel proceedings: a patent infringement lawsuit filed by Data Health Partners, Inc. against Teladoc Health, Inc. in the U.S. District Court for the District of Delaware (Case No. 1:23-cv-00160), and an Inter Partes Review (IPR) initiated by Teladoc Health Inc. challenging one of the asserted patents at the Patent Trial and Appeal Board (PTAB) (IPR2024-00616).

Chronological Summary:

• 2023-02-13: District Court Complaint Filed. Data Health Partners, Inc. ("Data Health") filed an original complaint for patent infringement against Teladoc Health, Inc. ("Teladoc") in the U.S. District Court for the District of Delaware.
• 2023-06-23: Amended Complaint Filed. Data Health filed an amended complaint, alleging that Teladoc infringed U.S. Patent Nos. 10,061,812, 11,144,554, and 11,151,142 with its Livongo Blood Glucose Meter and corresponding diabetes management platform.
• 2023-09 (approx.): Motion to Dismiss Filed. Teladoc Health filed a motion to dismiss the infringement claims, arguing that the asserted patents claimed patent-ineligible subject matter under 35 U.S.C. § 101.
• 2024-02-28: IPR Petition Filed. Teladoc Health Inc. filed an IPR petition, IPR2024-00616, challenging the validity of U.S. Patent 11,144,554.
• 2024-05-20: District Court Denies Motion to Dismiss (in part). The District Court for the District of Delaware, with Judge Jennifer Choe-Groves presiding, denied in part Teladoc's motion to dismiss. The court found that a representative claim for the patents, including the '554 patent, was "directed to the non-abstract idea of improving the monitoring of patient goals and outcomes," thus satisfying the first step of the Alice test for patent eligibility.
• 2024-09-16: IPR Institution Decision. The PTAB instituted review for IPR2024-00616, challenging U.S. Patent 11,144,554. The PTAB also instituted IPR2024-00617, challenging the '142 Patent, on September 17, 2024.
• 2024-10-24: District Court Denies Stipulated Stay. The parties stipulated to stay the district court litigation pending the final written decisions in IPR2024-00616 and IPR2024-00617. However, on October 24, 2024, Judge Choe-Groves denied the stipulated stay without providing her reasoning.
• 2025-09-12: IPR Final Written Decision Issued. The Patent Trial and Appeal Board issued a Final Written Decision for IPR2024-00616 concerning U.S. Patent 11,144,554.

Outcome:

As of the current date, the explicit outcome of the Final Written Decision for IPR2024-00616 (i.e., whether the challenged claims of U.S. Patent 11,144,554 were found patentable or unpatentable) is not publicly available in the search results.

The district court litigation, Data Health Partners, Inc. v. Teladoc Health, Inc. (1:23-cv-00160-JCG), remains active following the partial denial of Teladoc's motion to dismiss and the denial of the stipulated stay. The case appears to be proceeding in the District of Delaware.

Teladoc Health Inc., as the Petitioner (plaintiff in this context) in IPR2024-00616, is represented by the following counsel:

• Jesse A. Salen

  • Role: Lead Counsel (implied by extensive patent litigation and IPR experience for Teladoc)
  • Firm: Sheppard, Mullin, Richter & Hampton LLP
  • Office Location: Del Mar, California
  • Experience: Mr. Salen is a seasoned trial attorney specializing in intellectual property litigation and patent prosecution, including Inter Partes Review (IPR) proceedings before the PTAB. He has a history of representing Teladoc in IPR challenges, such as IPR2015-00924, IPR2016-00100, IPR2016-00101, and IPR2016-01167, where he successfully challenged patents related to telemedicine software. His experience spans medical devices, pharmaceuticals, and wireless communications.

• Michael V. Solomita

  • Role: Lead Counsel (implied by extensive patent litigation and IPR experience for Teladoc)
  • Firm: Solomita Law, PLLC (previously a partner at Chadbourne & Parke LLP and Sheppard Mullin)
  • Office Location: New York, New York
  • Experience: Mr. Solomita is an experienced patent litigator with a strong background in challenging patent validity before the U.S. Patent and Trademark Office and handling cases in U.S. District Courts and the U.S. International Trade Commission. He has also served as in-house patent counsel for Panasonic Corporation in Japan, directing litigations and spearheading patent licensing programs.

This identification is based on public filings and attorney profiles indicating their representation of Teladoc in similar IPR and patent litigation matters, including their explicit mention as attorneys for Teladoc in a PTAB context related to previous IPRs and their appearance for Teladoc Health Inc. in related district court patent litigation.

Data Health Partners Inc., the patent owner in IPR2024-00616, is represented by attorneys from Susman Godfrey L.L.P. and Farnan LLP. While specific counsel for IPR2024-00616 were not directly identified through public PTAB dockets via general web search, these firms represent Data Health Partners Inc. in the closely related district court patent infringement case, Data Health Partners, Inc. v. Teladoc Health, Inc. (Case No. 1:23-cv-00160, D. Del.), which involves the same patents. It is a common practice for legal teams to handle both district court litigation and parallel inter partes review (IPR) proceedings.

Here is the identified counsel for Data Health Partners Inc.:

• Barry C. Barnett

  • Role: Lead Counsel (implied, as partner in charge of the Data Health case in district court).
  • Firm: Susman Godfrey L.L.P., Houston, TX, and New York, NY.
  • Experience Note: A highly regarded trial lawyer, recognized as "Lawyer of the Year" for Patent Litigation in Houston by Best Lawyers in America (2020), with over three decades of experience in complex commercial and intellectual property litigation.

• Monica Daegele

  • Role: Trial Team (Associate).
  • Firm: Susman Godfrey L.L.P. (office location not specified in search results, but firm has offices in Houston, Dallas, Los Angeles, Seattle, and New York).
  • Experience Note: Serves on the Data Health trial team, contributing to patent litigation efforts.

• Santos Garza

  • Role: Intellectual Property Advisor (on trial team).
  • Firm: Susman Godfrey L.L.P. (office location not specified in search results).
  • Experience Note: Provides intellectual property advisory support to the Data Health trial team.

• Brian E. Farnan

  • Role: Local Counsel (Delaware counsel in related district court case, likely also serving in IPR).
  • Firm: Farnan LLP, Wilmington, DE.
  • Experience Note: A key player in the Delaware IP market, particularly in patent litigation, with extensive experience in jury and bench trials in federal and state courts in Delaware, often representing patent holders.